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Acute myeloid leukemia (AML) with inversion of chromosome 3 is characterized by overex-
pression of EVI1 and carries a dismal prognosis. Arsenic-containing compounds have been
described to be efficacious in malignancies overexpressing EVI1. Here, we describe a case
of AML with inv(3)(q21q26.2) treated with the organic arsenical darinaparsin. Using a “per-
sonalized medicine approach,” two different arsenicals were screened for anti-leukemic
effect against the patient’s cells ex vivo.The most promising compound, darinaparsin, was
selected for in vivo treatment. Clinical effect was almost immediate, with a normalization
of temperature, a stabilization of white blood cell (WBC) counts and an increased quality
of life. Longitudinal monitoring of patient response and resistance incorporating significant
correlative studies on patient-derived blood samples over the two cycles of darinaparsin
given to this patient allowed us to evaluate potential mechanisms of response and resis-
tance.The anti-leukemic effects of darinaparsin correlated with inhibition of the alternative
NF-κB pathway and production of the inflammatory cytokine IL-8. Emergence of resistance
was suspected during treatment cycle 2 and supported by xenograft studies in nude mice.
Darinaparsin resistance correlated with an attenuation of the effect of treatment on the
alternative NF-κB pathway.The results from this patient indicate that darinaparsin may be a
good treatment option for inv(3) AML and that inhibition of the alternative NF-κB pathway
may be predictive of response. Longitudinal monitoring of disease response as well as sev-
eral correlative parameters allowed for the generation of novel correlations and predictors
of response to experimental therapy in a heavily pretreated patient.
Keywords: acute myeloid leukemia, inv(3)(q21q26.2), darinaparsin, experimental treatment, resistance,
personalized medicine
INTRODUCTION
Acute myeloid leukemia (AML) with inversion or translocation of
the long arm of chromosome 3 (inv(3; q21q26.2)/t(3;3; q21;q26.2),
hereafter referred to as “inv(3)/t(3;3) AML” accounts for 1–2% of
AML cases and predicts an extremely poor prognosis, with a 5-
year overall survival of 5.7% (Lugthart et al., 2010). Due to the
distinct clinicopathologic attributes associated with these chro-
mosomal aberrations, inv(3)/t(3;3) AML has been included as
a separate sub-category of “AML with recurrent genetic abnor-
malities” in the latest WHO classification (Swerdlow et al., 2008).
Despite a characteristic clinical picture with a well-defined under-
lying molecular pathology, no targeted therapy currently exists for
inv(3)/t(3;3) AML, although improved treatment regimens clearly
are needed, as reflected by the poor overall performance of this
patient category.
Molecularly, inv(3)/t(3;3) AML is characterized by the aber-
rant juxtaposition of the oncogene ecotropic viral integration
site 1 (EVI1), with regulatory elements of ribophorin 1 (RPN1),
resulting in overexpression of EVI1 (Buonamici et al., 2003).
EVI1 is a transcription factor with a well-recognized role in the
normal development of the hematopoietic system. It has been
reported to function primarily as a transcriptional repressor, how-
ever, examples of an activating role in gene expression have also
been described (Yuasa et al., 2005; Lugthart et al., 2011). Arsenic
trioxide (ATO), an inorganic arsenical, has been investigated as a
potential therapy for hematological diseases overexpressing EVI1.
Shackelford et al. (2006) found that super-pharmacologic con-
centrations of ATO degrade EVI1, as well as several fusion pro-
teins containing EVI1, in cell line models of AML. A clinical
trial investigating the effect of ATO in combination with thalido-
mide in myelodysplastic syndrome (MDS), reported hematologic
responses in three out of five patients with overexpression of EVI1,
including responses in two out of three patients with inv(3)/t(3;3)
(Raza et al., 2004). Here,we describe the treatment of a patient with
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inv(3) AML with the organic arsenical darinaparsin (reviewed in
Mann et al., 2009). Although EVI1 expression was not modulated
following treatment, we did monitor the response and devel-
opment of resistance to darinaparsin. By assessing tumor gene
expression longitudinally within the patient, we found changes
in the alternative NF-κB pathway to be important correlates with
response.
RESULTS
MEDICAL HISTORY AND PRE-TREATMENT INVESTIGATIONS
The patient was diagnosed with AML in 2005 at the age of 30.
The karyotype performed on bone marrow cells at diagnosis was
46,XX,inv(3)(q21q26.2)× 2[21](Figure 1A). She initially under-
went two induction regimens followed by an allogeneic stem cell
transplant, resulting in a complete remission. After 5 years, the
patient’s AML relapsed and she received a total of seven dif-
ferent chemotherapy-containing regimens in an effort to try to
control her disease (see Table 1 for details). Fluorescent in situ
hybridization experiments confirmed the presence of a biallelic
inversion of chromosome 3 (Figure 1B). Given previous reports
suggesting that malignant cells with inv(3) might be sensitive
to ATO, cells from the patient’s bone marrow were collected
to determine response to arsenicals ex vivo (Raza et al., 2004;
Shackelford et al., 2006). As shown in Figure 1C, treatment with
therapeutically attainable concentrations of darinaparsin induced
significant cell-death, while ATO treatment only resulted in a neg-
ligible increase in cell death (Tsimberidou et al., 2009). Of note,
ATO (As2O3) contains twice as much arsenic per mole as dari-
naparsin (C12H22AsN3O6S), thus, 1µM ATO contains equivalent
amounts of arsenic as 2µM darinaparsin. Given these results, we
requested approval from Health Canada to treat the patient with
darinaparsin. However, her leukemia progressed rapidly, requiring
additional high-dose salvage chemotherapy to control her disease
before approval to administer darinaparsin could be obtained.
Following the last high-dose regimen, the patient was hospital-
ized with cytopenia, persistent fever, and poor general condition
corresponding to an ECOG performance status of 2. Ex vivo treat-
ment of the patient’s peripheral blood mononuclear cells (PBMCs)
immediately prior to starting darinaparsin treatment confirmed
that tumor cell sensitivity to darinaparsin was intact (Figure 1D).
CLINICAL RESPONSE TO DARINAPARSIN TREATMENT
Peripheral white blood cell (WBC) counts were measured each
time the patient was seen at the hospital. As shown in Figure 2A,
darinaparsin immediately reduced the patient’s WBC counts and
this effect was maintained while the patient remained on drug.
The wave-like pattern in WBC counts, with two troughs per treat-
ment cycle, suggests that darinaparsin exerted both immediate
FIGURE 1 | Metaphase karyotype from initial diagnosis (A) and
fluorescence in situ hybridization performed at relapse (B) showing
biallelic inversion of chromosome 3 (arrows). Also shown are two
intact copies of chromosome 7 in this patient (A). Mononuclear
cells isolated by Ficoll gradient separation from bone marrow
aspirate (C) and peripheral blood (D) were treated ex vivo for 48 h
with the indicated doses of arsenic trioxide (ATO) and darinaparsin
(Dar) to assess sensitivity to arsenicals. Cell death was measured as
the percentage of cells with sub-G0 DNA content. Error bars
indicate SEM.
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Table 1 | List of regimens used to treat the patient.
Date Treatment
April to May 2005 Two induction regimens:
(1) Cytarabine+daunorubicin (7+3)
(2) Cytarabine+ idarubicin (4+3)
September 2005 Pre-transplant mobilization:
Cyclophosphamide+ total body irradiation
September 2005 Allogeneic stem cell transplant
August to September 2010 Three high-dose regimens:
(1) FLAG-Ida (fludarabine, cytarabine,
G-CSF, and idarubicin)
(2) High-dose cytarabine
(3) Etoposide
November 2010 Investigational treatment:
Low-dose cytarabine+ ribavirin
December 2010 Three salvage chemotherapy regimens:
(1) Mitoxantrone
(2) Hydroxyurea
(3) Etoposide+ cyclophosphamide
January to February 2011 Investigational treatment:
Darinaparsin
anti-cancer effects and more delayed effects. Microscopy of
peripheral blood smears, showing nuclear blebbing, suggests cells
were dying by apoptosis (Figure 2B). Induction of apoptosis has
previously been described as a mechanism of anti-cancer activity
of darinaparsin (Matulis et al., 2009).
Within 10 h of the first darinaparsin infusion, the patient’s
fever (Figure 2C) and night sweats resolved and she regained
her appetite and energy. She was discharged home 3 days after
receiving the last dose of the first cycle. She enjoyed a good qual-
ity of life, with an ECOG performance status of 1 for more than
30 days, while undergoing her second cycle of darinaparsin as an
outpatient. Treatment was well tolerated with no observed side
effects. The patient died from extramedullary manifestations and
progression of her AML 36 days after receiving the first dose of
darinaparsin.
Given the rapid resolution of the patient’s symptoms fol-
lowing darinaparsin administration, we profiled levels of pro-
inflammatory cytokines in plasma in response to treatment using
a flow cytometry-based multiplex immunoassay kit. While all but
three of the 11 cytokines investigated were below the limit of detec-
tion of the assay, high levels of interleukin (IL)-8 were detected
prior to starting treatment (Figure 2C). IL-8 has both pro-survival
and pro-proliferative properties and has previously been shown to
be increased in AML patients (Waugh and Wilson, 2008; Kornblau
et al., 2010). The patient’s pre-treatment IL-8 levels were about
10 times higher than what has been reported for normal con-
trols (Kornblau et al., 2010). Interestingly, the changes observed in
IL-8 plasma levels in response to darinaparsin treatment mirror
the changes seen in the patient’s WBC counts (Figure 2A) and
temperature (Figure 2C), suggesting that darinaparsin impacts
temperature, as well as levels of leukemic cells and inflammatory
cytokines (these effects may well be related) and that this may
underlie the marked subjective and objective improvement in the
patient’s symptoms. Pearson correlation coefficients between IL-8
expression, temperature, and WBC counts suggest that these three
variables are indeed strongly positively related (Table 2).
To determine whether the delayed effects were due to arsenic
accumulation in the patient, we measured elemental arsenic levels
in patient plasma and PBMCs. Arsenic levels in plasma increased
within the first 24 h of treatment and continually rose throughout
the treatment period (Figure 2D). After 4–5 days off drug, plasma
arsenic levels returned to baseline. Arsenic levels in PBMCs rose
slower than plasma levels and remained elevated for several days
after discontinuation of darinaparsin (Figure 2E). Thus, while it
does not appear that arsenic accumulates in patient plasma under
this dosing regimen, it seems that high arsenic levels in PBMCs are
maintained several days after discontinuation of darinaparsin.
LABORATORY AND CORRELATIVE INVESTIGATIONS
By continuously sampling during the treatment of this patient,
we were able to perform correlative studies to investigate poten-
tial markers of response and resistance. A defining molecular
pathology of inv(3)/t(3;3) AML is the aberrant overexpression
of EVI1. Previous studies suggested that arsenic could decrease
EVI1 expression, potentially contributing to the cytotoxic effects
(Raza et al., 2004; Shackelford et al., 2006). To ascertain the effect
of darinaparsin on EVI1, we first analyzed EVI1 protein expres-
sion levels in PBMCs by immunoblot. No change in EVI1 pro-
tein was observed during the first 72 h of darinaparsin treatment
(Figure 3A). After 72 h, there was significant hemolysis of blood
samples, preventing reliable quantification at later time-points.
We also assessed whether the effect of darinaparsin observed
in this patient was due to inhibition of EVI1’s gene regulatory
activity by analyzing the expression levels of the tumor suppres-
sor PTEN, a target gene repressed by EVI1, by quantitative PCR
and western blot (Yoshimi et al., 2011). No induction of PTEN
mRNA or protein was observed during the first 72 h of treatment
(Figures 3A,B).
In order to determine the reproducibility of our results
obtained in a single patient, we treated the EVI1-expressing
myeloid leukemia cell line K562 with ATO and darinaparsin for
24 and 48 hours. Analogous to what was observed in primary
leukemic cells (Figures 1C,D), K562 cells were more sensitive to
darinaparsin than to ATO treatment (Figure 3C) while neither
darinaparsin nor ATO treatment modulated expression of EVI1
protein levels in K562 cells (Figure 3D). Thus, our results do not
support modulation of EVI1 expression or repressive activity as
part of the anti-leukemic mechanism of darinaparsin in either
EVI1-expressing primary cells or cell lines. Note that decreased
EVI1 mRNA expression was only described after several months
in MDS patients treated with ATO and thalidomide (Raza et al.,
2004).
POTENTIAL MECHANISM OF SENSITIVITY/RESISTANCE
Comparison of the in vivo WBC response to darinaparsin dur-
ing cycle 1 with the response during cycle 2 suggests the emer-
gence of resistance to darinaparsin (Figure 2A). In particular,
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FIGURE 2 | (A) White blood cell counts were measured every time the
patient was seen at our institution. The beginning and end of cycles of
darinaparsin treatment are demarcated with vertical lines. Note that the
x -axis is not to scale. (B) Micrograph of peripheral blood smear stained
with Wright’s Giemsa stain while the patient was on darinaparsin
treatment. Nuclear blebbing suggests cells are dying by apoptosis.
(C) While the patient was in hospital, her temperature was monitored daily
(measured in degrees Celsius). The temperature curve has been overlaid
graphs showing expression of circulating cytokines in plasma, measured
by a multiplex immunoassay kit. Only three out of the 11 cytokines
measured by the kit were detected at levels above the assay’s limit of
detection. IL-8, interleukin 8; IL-10, interleukin 10; TNF-α, tumor necrosis
factor-alpha. Samples taken prior to starting treatment with darinaparsin
are labeled “Pre” while time points during and after darinaparsin treatment
are labeled with cycle number (C1, cycle 1; h, hours; d, days) and time on
or off darinaparsin treatment. The patient was allowed to go home 3 days
after completing her first course of darinaparsin. Elemental arsenic levels
were measured in patient plasma (D) and peripheral blood mononuclear
cells (PBMCs) (E) by inductively coupled plasma mass spectrometry. The
highest plasma level of arsenic measured with this dosing schedule was
approximately 90 parts per billion (ppb). Given arsenic’s molar mass of
75 g/mol, this is equal to a plasma concentration of 1.2µM, which
corresponds well with the doses used for ex vivo experiments in
Figures 1C,D.
the increase in WBC counts after darinaparsin infusion was
stopped is greater in cycle 2 than in cycle 1. While the patient
was still at home, enjoying a good quality of life at this time,
these results suggest that resistance to darinaparsin was starting
to develop. Further evidence of a resistant phenotype was pro-
vided by xenograft studies in nude mice (Figure 4). In order
to measure levels of leukemia initiating cells, we measured the
engraftment of patient-derived PBMCs from a pre-treatment
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FIGURE 3 | (A) Western blot of full-length ecotropic viral integration
site 1 (EVI1), a truncated form of EVI1 (EVI1 ∆) and PTEN expression in
peripheral blood mononuclear cells at the time points indicated. No
fusion of EVI1 and MDS1 was detected in these cells. GAPDH is
included as a loading control. (B) Levels of PTEN mRNA measured by
qPCR. Expression levels are shown as PTEN ∆∆ct/GAPDH ∆∆ct. Error
bars indicate SEM. No statistically significant differences in mRNA
levels were found. (C) K562 chronic myeloid leukemia cells were
treated for 48 h with the indicated doses of arsenic trioxide (ATO) and
darinaparsin (Dar) to assess sensitivity to arsenicals. Cell death was
measured as the percentage of cells with sub-G0 DNA content. Error
bars indicate SEM. (D) Western blot of EVI1 in K562 cells treated for
24 h with the indicated doses of ATO and darinaparsin (Dar). GAPDH is
included as a loading control.
blood sample compared to PBMCs isolated during cycle 2.
Engraftment is predictive of the number of leukemia initiating
cells. Patient PBMCs isolated after 48 h of darinaparsin treat-
ment during cycle 2 showed greater levels of mouse marrow
engraftment than pre-treatment PBMCs, suggesting elevated lev-
els of leukemia initiating cells in the post-treatment sample from
cycle 2.
To explore potential mechanisms of resistance to darina-
parsin, we performed cDNA microarray analyses on PBMCs prior
to and 48 h after the start of each cycle of darinaparsin. The
alternative NF-κB pathway was identified as one of the most
modulated pathways during the course of darinaparsin treat-
ment using Ingenuity Systems Pathway Analysis (Figure 5A, left
panel). Expression patterns of three genes in the alternative NF-
κB pathway were validated by quantitative PCR using gene-specific
primers as shown in Figure 5B. There is good agreement between
results obtained by microarray and quantitative PCR. Darina-
parsin decreased expression of several members of the alternative
NF-κB pathway after 48 h of treatment. This correlates with the
observed decrease in production of IL-8 (Figure 2C), a well-
characterized NF-κB target gene. Furthermore, gene expression
in PBMCs prior to the second cycle of darinaparsin revealed an
upregulated alternative NF-κB pathway that was not inhibited
by darinaparsin during the second cycle, perhaps foreshadowing
the emergence of resistance (Figure 5A, center and right pan-
els). The attenuation of the response of the alternative NF-κB
FIGURE 4 | Percentage of engraftment in NOD/SCID/IL2Rγc mice for the
indicated cells. Each symbol represents a single animal analyzed 12 weeks
after transplantation, mean engraftment is indicated by horizontal bars.The
percentage of human CD45 in the BM was determined via flow cytometry.
pathway to darinaparsin treatment coincides with emergence of
resistance, thereby strengthening the hypothesis that this pathway
plays a role in the sensitivity/resistance of inv(3) AML cells to
darinaparsin.
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FIGURE 5 | (A) Microarray analyses were performed on RNA isolated from
peripheral blood mononuclear cells before and 48 h after the start of each
cycle of darinaparsin using Agilent Human 60 K expression arrays. The
TNFR2/NF-κB alternative signaling pathway was identified as significantly
changed (p=3.09×10−3). Symbols denote gene function (see legend on
right). (B) Validation of expression of selected genes from the alternative
NF-κB pathway (BIRC3, NFKB2, and TNFRSF1B) reveals good agreement with
results from microarray analysis. Expression levels are shown as NF-κB
pathway ∆∆ct/GAPDH ∆∆ct. Error bars indicate SEM. BIRC3, baculoviral IAP
repeat containing 3; NFKB2, nuclear factor of kappa light polypeptide gene
enhancer in B-cells 2; TNFRSF1B, tumor necrosis factor receptor superfamily,
member 1B.
DISCUSSION
Herein, we describe for the first time the treatment of a patient
with inv(3) AML with the organic arsenical darinaparsin. Darina-
parsin stabilized disease in a heavily pretreated patient and greatly
improved quality of life. Therapy was well tolerated with almost
immediate clinical benefit and no observed side effects. Clinical
benefit was suggested by a simple ex vivo cell-death assay per-
formed prior to starting therapy, indicating that this may be useful
as a predictive marker of in vivo response. Unexpectedly, we did
not find evidence that treatment directly affected EVI1 levels or
activity. Instead, our results indicate that inhibition of the alterna-
tive NF-κB pathway by darinaparsin correlated with response and
plasma levels of the inflammatory cytokine IL-8.
The strategy outlined here serves as an example of the power
of a personalized medicine approach in patients for whom no
accepted standard therapy is available. In particular, for patients
suffering from uncommon types of malignancies, it is imperative
to gather as much information on treatment effect, response, and
resistance at every given opportunity. This series of experiments
highlights how multiple platforms can be used to assess mecha-
nisms of response and resistance. Here, we included everything
from genomics to in vivo stem cell analysis.
In this specific case, the literature suggested that arsenicals
might be efficacious in malignancies with inv(3), thus we tested
two arsenicals using a simple ex vivo death assay. Interestingly,
the drug that performed the best in our ex vivo assay was not
ATO [the drug for which activity in inv(3) malignancies had
previously been reported], but rather the organic arsenical dari-
naparsin (Raza et al., 2004; Shackelford et al., 2006; Mann et al.,
2009). Darinaparsin has previously been tested in hematologi-
cal malignancies, including acute leukemias (Clinical trial ID:
NCT00592046). Encouragingly, the patient experienced marked
subjective and objective improvement after starting darinaparsin,
however, after about a month, her condition rapidly deteriorated.
Our results highlight a key advantage of longitudinal sampling
of the same patient over his or her entire disease trajectory. The
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availability of blood samples from both the time during which the
malignant cells exhibited sensitivity to treatment (cycle 1) and the
time at which resistance was starting to become apparent (cycle 2)
allowed us to compare treatment responses at these time points.
Using an unbiased gene expression based approach, we identified
the alternative NF-κB pathway as being constitutively activated
in the patient’s AML blasts prior to treatment and showed that
this activation was attenuated after 48 h of darinaparsin. However,
prior to the start of cycle 2, the NF-κB pathway was upregulated
further and was no longer responsive to darinaparsin treatment
(Figure 5). The abrogation of a putative mechanism of response
at the time of emergence of resistance strengthens the hypothesis
that this pathway plays an important role in resistance/sensitivity
to darinaparsin in this patient. Levels of circulating IL-8 in plasma
may function as a surrogate marker of NF-κB pathway activation
and could conceivably be used to monitor treatment response in
IL-8 secreting AML.
Based on the results outlined above, further investigation is
warranted into (1) EVI1 overexpressing AMLs and (2) AMLs with
activation of the alternative NF-κB pathway as potential targets for
darinaparsin treatment.
MATERIALS AND METHODS
All clinical investigations and treatments were performed with
patient consent under a compassionate use protocol approved
by the Jewish General Hospital Research Ethics Committee and
Health Canada.
CELLS
K562 cells were purchased from ATCC and grown in IMDM
medium supplemented with 10% fetal bovine serum and
antibiotics.
STANDARD CYTOGENETICS AND FISH
G-banded karyotypes were obtained from bone marrow mononu-
clear cells according to standard cytogenetic procedures and
described according to the International System for Human Cyto-
genetic Nomenclature 2009. FISH experiments were performed
on interphasic nuclei and metaphases using the EVI1 Breakapart
probe LPH036 (Cytocell, Cambridge, UK).
SAMPLE PREPARATION
Peripheral blood was collected in heparin tubes prior to starting
treatment and every time the patient was seen in hospital. The
blood was spun down to remove the plasma (stored at−80˚C) fol-
lowed by isolation of PBMCs by Ficoll gradient separation. RNA,
DNA, and whole cell extracts were isolated as described below. Sur-
plus PBMCs were frozen in 10% DMSO/90% fetal bovine serum
at−80˚C.
PROPIDIUM IODIDE (PI) STAIN OF EX VIVO TREATED BONE MARROW
CELLS AND PBMCs
For a detailed description see Hardin et al. (1992). Briefly, cells
were washed once in FACS wash buffer (5 mM NaN3 in PBS sup-
plemented with 5% fetal bovine serum) and then stained with
50µg/mL PI (Sigma) in hypotonic buffer (0.1% sodium cit-
rate and 0.1% Triton X-100 in ddH20). Approximately 500,000
cells/condition were stained with 0.5 mL PI stain and analyzed
on a BD Biosciences FACSCalibur flow cytometer. Cell death was
measured as the percentage of cells with sub-G0 DNA content.
ICP-MS
Elemental arsenic levels were measured in patient plasma and
PBMCs by inductively coupled plasma mass spectrometry (Chem-
ical Solutions Ltd, Mechanicsburg, PA, USA).
IMMUNOBLOTTING
Whole cell extracts were made from patient samples and K562
cells using Tris/NaCl/triton x-100 buffer (50 mM Tris-HCl pH 8.0,
150 mM NaCl and 1% triton X-100 supplemented with protease
inhibitor cocktail (Roche) and PhosStop (Roche)(. Proteins were
separated by SDS-PAGE and transferred to nitrocellulose mem-
brane. Primary antibodies for PTEN, EVI1, and GAPDH were
all purchased from Cell Signaling. Specific binding was detected
with horseradish peroxidase-labeled secondary antibodies and
visualized with enhanced chemiluminescence.
qPCR
RNA was extracted from patient samples using Qiagen All-
Prep DNA/RNA mini kit. RNA was converted to cDNA using
Superscript II reverse transcriptase (Invitrogen). Specific qPCR
amplification was performed using a 7500 Fast Thermocycler
(Applied Biosystems) and either Taqman chemistry (PTEN, 18S,
and GAPDH) or SYBR green chemistry and specific primers.
BIRC3: 5′-TCC GTC AAG TTC AAG CCA GTT-3′ and 5′-GGG
CTG TCT GAT GTG GAT AGC-3′; TNFSF1B: 5′-GGC CAG ACC
AGG AAC TGA AA-3′ and 5′-GAT GAA GTC GTG TTG GAG
AAC GT-3′; and NFkB2: 5′-ACG AGG GAC CAG CCA AGA T-3′
and 5′-GCA CGA GGT GGG TCA CTG T-3′.
CIRCULATING CYTOKINE DETERMINATION
Cytokine profiling of patient plasma samples was done using a
Human Th1/Th2 11plex FlowCytomix Multiplex kit (eBioscience,
San Diego, CA, USA) according to the manufacturer’s instructions.
MOUSE WORK
Studies were performed with approval from the Uni-
versity of Rochester Institutional Review Board, IUCOC.
Table 2 | Calculation of Pearson correlation coefficients for the relation
of temperature, white blood cell counts, and interleukin 8 (IL-8)
plasma concentration.
Date IL-8 Conc.
(pg/mL)
Temp.
(Celsius)
WBC counts
+1 day
11 January 2011 99.36 38.3 45.1
12 January 2011 41.69 36.8 33.5
13 January 2011 56.53 36.4 30.3
18 January 2011 170.4 38.6 46.1
Pearson IL-8 vs Temp.
Correlation co-eff: 0.883715871
Pearson IL-8 vs WBC+1day
Correlation co-eff: 0.854039474
Pearson Temp. vs WBC+1day
Correlation co-eff: 0.998008274
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NOD/SCID/IL2Rγc mice were sublethally irradiated with 2.7 Gy
(270 rad) using a RadSource X-ray irradiator (RadSource, Boca
Raton, FL, USA) the day before transplantation. Cells to be assayed
were thawed, counted, and then injected via tail vein in a final vol-
ume of 0.2 mL of PBS with 0.5% FBS. After 12 weeks, animals were
sacrificed and BM was collected. To determine human cell engraft-
ment the BM cells were labeled with antihuman CD45 (Becton
Dickinson) and analyzed via flow cytometry.
GENE EXPRESSION PROFILING
Microarray analyses were performed using Agilent (Mississauga,
ON,USA) Human 60 K expression arrays at Genome Quebec. Data
were analyzed using FlexArray and Ingenuity Pathway Analysis
Software.
Raw text files for the one-color Agilent array were imported in
R version 2.14.0 using the package limma (PMID 16646809). We
processed the data by first subtracting the background using norm-
exp, took the log2 of the remaining intensity and applied quantile
normalization to the entire set of arrays. Differential expression
of genes was computed using limma (PMID 16646809). We con-
sidered genes as differentially expressed if the mean normalized
signal of the two conditions is higher than five and the differential
expression is greater than twofold change.
PATIENT TREATMENT PROTOCOL
Darinaparsin (300 mg/m2) was administered by intravenous infu-
sion on five consecutive days followed by 16 days off drug.
Following the end of the first 21-day cycle, this protocol was
repeated for cycle 2.
STATISTICS
For in vitro experiments, all error-bars represent the standard error
of the mean of three replicates. Significance was determined by
one-way analysis of variance followed by Newman–Keuls post-
tests using Prism version 3.0 (GraphPad software, San Diego, CA,
USA). For the mouse work, significance was calculated using an
unpaired t -test (two-tailed).
∗, p< 0.05; ∗∗, p< 0.01; ∗∗∗, p< 0.001.
Pearson correlations in Table 2 were calculated using the
correlation function in Microsoft Excel with the data points
shown.
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